Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Shanghai Junshi Biosciences Co Ltd (Junshi Biosciences) is a biopharmaceutical company that discovers, develops and commercialization of novel therapies for autoimmune diseases, metabolic diseases and infectious diseases. The company’s pipeline products include JS212, JS213, JS207, JS203, JS214, JS015, JS001sc which treats tumors; JS111 targets non-small cell lung cancer; JS110 for endometrial cancer; JS007 targets lung cancer, melanoma; JT002 for seasonal allergic rhinitis; tifcemalimab which treats lung cancer and lymphoma; roconkibart targets psoriatic and spondylitis; JS105 for gynecological tumors; and JS107 treats gastrointestinal cancer. It offers marketed products including toripalimab which targets tumors; adalimumab for rheumatoid arthritis; mindeudesivir hydrobromide treats COVID-19; ongericimab for hyperlipidemia. The company operates in China and the US. Junshi Biosciences is headquartered in Shanghai, China.
Headquarters
China
Address
16f, Building 7, No. 6, Lane 100, Pingjiaqiao Road, Pudong New Area, Shanghai, 100000
Website
www.junshipharma.com
Telephone
86 21 61058800
No of Employees
2,903
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
1877 (HKG)
Revenue (2024)
$347.6M
28.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
34.4%
(2024 vs 2023)
Market Cap*
$4.7B
Net Profit Margin (2024)
XYZ
48.9%
(2024 vs 2023)
* As of and is in US$
Shanghai Junshi Biosciences Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | TUOYI |
| Tumors: | LOQTORZI |
| JS212 | ZYTORVI |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In July, the company entered into a licensing agreement with Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. to develop, register, produce, and commercialize rucozybimab (JS005, anti-IL-17A monoclonal antibody) in the Greater China region. |
| 2026 | Plans/Strategy | In June, the company announced its plans to sell its 27.27% stake to Med-Fine Venture Fund I. |
| 2025 | Regulatory Approval | In December, the company received acceptance from the National Medical Products Administration for Roconkibart injection to treat adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. |
Competitor Comparison
| Key Parameters | Shanghai Junshi Biosciences Co Ltd | Innovent Biologics Inc | Akeso Inc | InnoCare Pharma Ltd | Ascletis Pharma Inc |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shanghai | Suzhou | Zhongshan | Beijing | Hangzhou |
| State/Province | Shanghai | Jiangsu | Guangdong | Beijing | Zhejiang |
| No. of Employees | 2,903 | 7,502 | 3,761 | 1,259 | 231 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Xiong Jun | Chairman | Executive Board | 2018 | 52 |
| NING LI | Vice Chairman | Executive Board | 2024 | 65 |
| Zhang Zhuobing | Director; Deputy General Manager | Executive Board | 2018 | 59 |
| SHENG YAO | Director; Deputy General Manager | Executive Board | 2018 | 51 |
| Zou Jianjun | General Manager; Director | Executive Board | 2024 | 55 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer